BENITEC BIOPHAR/S (NASDAQ:BNTC) shares saw unusually-high trading volume on Wednesday . Approximately 1,227,118 shares changed hands during mid-day trading, an increase of 5,989% from the previous session’s volume of 20,152 shares.The stock last traded at $0.85 and had previously closed at $0.66.
The stock’s 50 day simple moving average is $0.74.
About BENITEC BIOPHAR/S (NASDAQ:BNTC)
Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B.
See Also: Why are percentage gainers important?
Receive News & Ratings for BENITEC BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BENITEC BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.